Screener
ImmunityBio, Inc. IBRX Reportable Segment — Gross Profit
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | $44,206 | $16,517 |
| Cost of sales | 238 | 58 |
| Gross profit | 43,968 | 16,459 |
| Operating expenses | ||
| External research and development expense (including amounts with related parties) (1) | 20,082 | 5,511 |
| Internal research and development expense (including amounts with related parties): (2) | ||
| Personnel-related costs | 25,850 | 23,065 |
| Equipment, depreciation, and facility costs | 13,588 | 13,192 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — gross profit?
- ImmunityBio, Inc. (IBRX) reported reportable segment — gross profit of $43.97M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — gross profit changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — gross profit increased by 167.1% year-over-year, from $16.46M to $43.97M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — gross profit?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — gross profit has grown at a 1245.1% compound annual growth rate (CAGR), from $622K to $112.54M.
- What does reportable segment — gross profit mean?
- Calculated as the segment's total revenue minus its direct cost of sales. It serves as a primary indicator of the segment's core operational efficiency and pricing power before considering overhead expenses.
Ask your AI about ImmunityBio, Inc.'s reportable segment — gross profit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude